{"id":56508,"date":"2026-02-06T21:13:28","date_gmt":"2026-02-06T13:13:28","guid":{"rendered":"https:\/\/flcube.com\/?p=56508"},"modified":"2026-02-06T21:13:29","modified_gmt":"2026-02-06T13:13:29","slug":"everest-medicines-files-velsipity-for-ulcerative-colitis-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56508","title":{"rendered":"Everest Medicines Files Velsipity for Ulcerative Colitis in China"},"content":{"rendered":"\n<p><strong>Everest Medicines<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1952:HKG\">HKG: 1952<\/a>) announced it has submitted a <strong>marketing filing<\/strong> in China for <strong>Velsipity (etrasimod)<\/strong> to treat adult patients with <strong>moderately to severely active ulcerative colitis (UC)<\/strong> who have had inadequate response, loss of response, or intolerance to conventional therapy or biologics. The next\u2011generation <strong>sphingosine\u20111\u2011phosphate (S1P) receptor modulator<\/strong> is already approved in <strong>12 global markets<\/strong>, including the US, EU, Japan, and Hong Kong.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-filing-amp-drug-profile\">Regulatory Filing &amp; Drug Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Everest Medicines (1952.HK)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Velsipity (etrasimod)<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Next\u2011generation S1P receptor modulator (targets S1P1, 4, 5)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderately to severely active ulcerative colitis (UC)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Inadequate response\/intolerance to conventional therapy or biologics<\/td><\/tr><tr><td><strong>Filing Status<\/strong><\/td><td>Marketing application submitted in China<\/td><\/tr><tr><td><strong>Originator<\/strong><\/td><td>Arena Pharmaceuticals (acquired by Pfizer 2022)<\/td><\/tr><tr><td><strong>Everest Rights<\/strong><\/td><td>Exclusive development, manufacturing, and commercialization rights in Greater China and South Korea (since 2017)<\/td><\/tr><tr><td><strong>Global Approvals<\/strong><\/td><td>US, EU, Canada, Japan, Australia, UK, Switzerland, Israel, Turkey, India, Singapore, Hong Kong, Macau<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China UC Market:<\/strong> Valued at <strong>\u00a58\u202fbillion<\/strong> (~US$1.1\u202fbillion) in 2025, growing at <strong>12% CAGR<\/strong> driven by biologics adoption<\/li>\n\n\n\n<li><strong>S1P Modulator Competition:<\/strong> Competes with <strong>Zeposia (Bristol Myers)<\/strong> and <strong>Mayzent (Novartis)<\/strong>; etrasimod\u2019s optimized S1P1\/4\/5 binding profile offers improved safety\/tolerability<\/li>\n\n\n\n<li><strong>Strategic Value:<\/strong> China filing represents final major market entry for Velsipity; completes Everest\u2019s gastroenterology franchise alongside xeligekimab<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a51.5\u20132.5\u202fbillion<\/strong> (US$210\u2013350\u202fmillion) peak annual sales in China by 2028, assuming 15% share of second\u2011line UC market<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> NMPA review expected <strong>12\u201318 months<\/strong>; potential approval <strong>Q2\u202f2027<\/strong>; commercial launch preparation underway<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory review timelines, commercial expectations, and revenue projections for Velsipity in China. Actual results may differ due to NMPA review outcomes, competitive dynamics, and market adoption rates.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Everest Medicines (HKG: 1952) announced it has submitted a marketing filing in China for Velsipity&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56509,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[126,1164,15],"class_list":["post-56508","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-everest-medicines","tag-hkg-1952","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Everest Medicines Files Velsipity for Ulcerative Colitis in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Everest Medicines (HKG: 1952) announced it has submitted a marketing filing in China for Velsipity (etrasimod) to treat adult patients with moderately to severely active ulcerative colitis (UC) who have had inadequate response, loss of response, or intolerance to conventional therapy or biologics. The next\u2011generation sphingosine\u20111\u2011phosphate (S1P) receptor modulator is already approved in 12 global markets, including the US, EU, Japan, and Hong Kong.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56508\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Everest Medicines Files Velsipity for Ulcerative Colitis in China\" \/>\n<meta property=\"og:description\" content=\"Everest Medicines (HKG: 1952) announced it has submitted a marketing filing in China for Velsipity (etrasimod) to treat adult patients with moderately to severely active ulcerative colitis (UC) who have had inadequate response, loss of response, or intolerance to conventional therapy or biologics. The next\u2011generation sphingosine\u20111\u2011phosphate (S1P) receptor modulator is already approved in 12 global markets, including the US, EU, Japan, and Hong Kong.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56508\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T13:13:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T13:13:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56508#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56508\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Everest Medicines Files Velsipity for Ulcerative Colitis in China\",\"datePublished\":\"2026-02-06T13:13:28+00:00\",\"dateModified\":\"2026-02-06T13:13:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56508\"},\"wordCount\":296,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56508#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0603.webp\",\"keywords\":[\"Everest Medicines\",\"HKG: 1952\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56508#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56508\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56508\",\"name\":\"Everest Medicines Files Velsipity for Ulcerative Colitis in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56508#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56508#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0603.webp\",\"datePublished\":\"2026-02-06T13:13:28+00:00\",\"dateModified\":\"2026-02-06T13:13:29+00:00\",\"description\":\"Everest Medicines (HKG: 1952) announced it has submitted a marketing filing in China for Velsipity (etrasimod) to treat adult patients with moderately to severely active ulcerative colitis (UC) who have had inadequate response, loss of response, or intolerance to conventional therapy or biologics. The next\u2011generation sphingosine\u20111\u2011phosphate (S1P) receptor modulator is already approved in 12 global markets, including the US, EU, Japan, and Hong Kong.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56508#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56508\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56508#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Everest Medicines Files Velsipity for Ulcerative Colitis in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56508#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Everest Medicines Files Velsipity for Ulcerative Colitis in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Everest Medicines Files Velsipity for Ulcerative Colitis in China - Insight, China&#039;s Pharmaceutical Industry","description":"Everest Medicines (HKG: 1952) announced it has submitted a marketing filing in China for Velsipity (etrasimod) to treat adult patients with moderately to severely active ulcerative colitis (UC) who have had inadequate response, loss of response, or intolerance to conventional therapy or biologics. The next\u2011generation sphingosine\u20111\u2011phosphate (S1P) receptor modulator is already approved in 12 global markets, including the US, EU, Japan, and Hong Kong.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56508","og_locale":"en_US","og_type":"article","og_title":"Everest Medicines Files Velsipity for Ulcerative Colitis in China","og_description":"Everest Medicines (HKG: 1952) announced it has submitted a marketing filing in China for Velsipity (etrasimod) to treat adult patients with moderately to severely active ulcerative colitis (UC) who have had inadequate response, loss of response, or intolerance to conventional therapy or biologics. The next\u2011generation sphingosine\u20111\u2011phosphate (S1P) receptor modulator is already approved in 12 global markets, including the US, EU, Japan, and Hong Kong.","og_url":"https:\/\/flcube.com\/?p=56508","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-06T13:13:28+00:00","article_modified_time":"2026-02-06T13:13:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56508#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56508"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Everest Medicines Files Velsipity for Ulcerative Colitis in China","datePublished":"2026-02-06T13:13:28+00:00","dateModified":"2026-02-06T13:13:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56508"},"wordCount":296,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56508#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0603.webp","keywords":["Everest Medicines","HKG: 1952","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56508#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56508","url":"https:\/\/flcube.com\/?p=56508","name":"Everest Medicines Files Velsipity for Ulcerative Colitis in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56508#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56508#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0603.webp","datePublished":"2026-02-06T13:13:28+00:00","dateModified":"2026-02-06T13:13:29+00:00","description":"Everest Medicines (HKG: 1952) announced it has submitted a marketing filing in China for Velsipity (etrasimod) to treat adult patients with moderately to severely active ulcerative colitis (UC) who have had inadequate response, loss of response, or intolerance to conventional therapy or biologics. The next\u2011generation sphingosine\u20111\u2011phosphate (S1P) receptor modulator is already approved in 12 global markets, including the US, EU, Japan, and Hong Kong.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56508#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56508"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56508#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0603.webp","width":1080,"height":608,"caption":"Everest Medicines Files Velsipity for Ulcerative Colitis in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56508#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Everest Medicines Files Velsipity for Ulcerative Colitis in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56508","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56508"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56508\/revisions"}],"predecessor-version":[{"id":56510,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56508\/revisions\/56510"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56509"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56508"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56508"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56508"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}